m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00598)
Name
LY-292223
Synonyms
2-(4-Morpholinyl)-4H-1-benzopyran-4-one; 2-morpholinochromone; LY-292223; CHEMBL367315; 2-morpholino-4H-chromen-4-one; 130735-56-7; U67154; AC1L2YUR; U-67154; SCHEMBL3361567; 2-morpholin-4-ylchromen-4-one; DTXSID30156701; 2-Morpholin-4-yl-chromen-4-one; QNFWERYZJLBANZ-UHFFFAOYSA-N; BDBM50098118; 2-(4-Morpholinyl)-4H-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-
    Click to Show/Hide
Status
Investigative
Structure
Formula
C13H13NO3
InChI
1S/C13H13NO3/c15-11-9-13(14-5-7-16-8-6-14)17-12-4-2-1-3-10(11)12/h1-4,9H,5-8H2
InChIKey
QNFWERYZJLBANZ-UHFFFAOYSA-N
PubChem CID
131255
TTD Drug ID
D07APP
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
PI3-kinase beta (PIK3CB)
Methyltransferase-like 13 (METTL13)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for LY-292223. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of LY-292223 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for LY-292223. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of LY-292223 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for LY-292223. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of LY-292223 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for LY-292223. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY-292223 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
References
Ref 1 N(6)-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut. 2020 Dec;69(12):2180-2192. doi: 10.1136/gutjnl-2019-320179. Epub 2020 Apr 20.
Ref 2 LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. doi: 10.1016/s0960-894x(01)00099-3.